Wainwright Marks Management – Strong wage growth could provide much needed support for UK economy facing stress of Brexit uncertainty.

Wainwright Marks Management - US economy enters 10th year of growth as global economic peers stumble.

Wainwright Marks Management - Rising unemployment could force Reserve Bank of Australia to cut interest rates.

Wainwright Marks Management - Companies in Germany and France say shortage of skilled labor is preventing businesses from expanding.

Wainwright Marks Management – Decline in labor productivity contributes to Australia's economic woes.

Wainwright Marks Management - European Commission will hold off on disciplinary proceedings against Italy, giving the debt burdened country time to revise its budget plans.

PRZOOM - Newswire (press release) - Tue, 12 Nov 2024 00:00:00 -0500, Phoenix AZ United States - Collaboratively developed Honeywell Connected Recorder-25 now available to meet 2024 FAA Reauthorization Act mandating longer recording capability [NASDAQ: HON] - Honeywell.com / CurtissWrightDS.com

Dawn Travel, an innovative leader in the luxury travel and cruise industry, is proud to announce that CEO Cliff Hawk will be a featured speaker at the 2024 Phocuswright Conference in Fort Lauderdale. Hawk will participate in the highly anticipated “New Technology and Startup” panel, sharing insights on the cutting-edge advancements driving the future of travel planning and luxury experiences. Dawn Travel has [PR.com]

Edgar Wright attends the 55th Annual International Cinematographers Guild Publicists Awards at The Beverly Hilton Hotel on March 2, 2018 in Beverly Hills, California.; Credit: Tommaso Boddi/Getty Images

The joke about Sparks — if you’ve even heard of them — is that it’s the best British band to come out of America. That confusion is why Edgar Wright, the director of “Baby Driver” and “Shaun of the Dead,” wanted to make his first documentary about the group, headed by brothers Ron and Russell Mael. Quite simply, Wright was tired of explaining who the band was and why he loves them. His documentary, called “The Sparks Brothers,” premiered at this year’s Sundance Film Festival. John Horn talked with Wright after its January premiere about his personal connection to the band, how he connected with the brother, the editing process of the documentary and more. The film is in theaters now.

With guest host John Horn

Guest: 

Edgar Wright, director of the new documentary “The Sparks Brothers;” he tweets @edgarwright

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Ed Arce 10/09/2024

H.C. Wainwright & Co. analysts Ed Arce and Thomas Yip, in a research report published on October 9, 2024, maintained a Buy rating on Unicycive Therapeutics Inc. (UNCY:NASDAQ) with a price target of US$2.50. The report follows Unicycive's announcement of the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.

Arce and Yip highlighted the significance of the study results, stating, "UNI-494 showed rapid metabolism, enabling the expected release of nicorandil and its linker." They added, "Importantly, PK results collected in the study showed fast absorption of UNI-494, with rapid metabolism leading to the expected release of nicorandil and its linker."

The analysts noted the safety profile of UNI-494, commenting, "UNI-494 was generally safe and well-tolerated; headache was the most common adverse event (AE), and all AEs were mild with no serious adverse events (SAEs) or AEs leading to withdrawal in Part 1."

Regarding Unicycive's strategic plans, the analysts stated, "Management plans to request a meeting with the FDA by year-end 2024 to review these Phase 1 results and discuss the design of a potential Phase 2 study in patients with acute kidney injury (AKI)."

The report also highlighted the pending milestone for Unicycive's other product candidate, Oxylanthanum Carbonate (OLC), noting, "We await the FDA's formal acceptance of the NDA for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis (we expect by November 2) with a PDUFA date assignment to further narrow OLC's potential approval timing."

H.C. Wainwright & Co.'s valuation methodology for Unicycive is based on a risk-adjusted Net Present Value (rNPV) model. The analysts explained, "We employ a rNPV valuation model to estimate the value of UNCY shares and arrive at our US$2.50 PT based on: (1) about US$2.30 per share for royalties on net sales of OLC in the U.S. and EU (85% PoS, US$149.1M global peak revenue in 2034); and (2) about US$0.25 per share for royalties on net sales of UNI-494 in the U.S. and EU for AKI (20% PoS; US$195M global peak revenue in 2036)."

They added, "In our valuation model, we employ a 14.5% discount rate, which we believe adequately reflects the overall risks of the Unicycive development pipeline. We conservatively assume zero terminal value after the end of the market exclusivity period that runs through 2037."

The analysts also outlined several risk factors, including regulatory, commercialization, market, intellectual property, and funding risks.

In conclusion, H.C. Wainwright & Co.'s maintenance of a Buy rating and US$2.50 price target reflects a positive outlook on Unicycive Therapeutics' potential in developing UNI-494 for AKI and OLC for hyperphosphatemia. The share price at the time of the report of US$0.36 represents a potential return of approximately 594% to the analysts' target price, highlighting the upside potential if the company's clinical development and regulatory plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Unicycive Therapeutics Inc., October 9, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Ed Arce and Thomas Yip , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Unicycive Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Unicycive Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Unicycive Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Unicycive Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: UNCY:NASDAQ, )

Source: Andrew Fein 10/23/2024

H.C. Wainwright & Co. analysts Andrew S. Fein, Matthew Caufield, Dr. Andres Y. Maldonado, and Dr. Ananda Ghosh, in a research report published on October 23, 2024, maintained a Buy rating on DBV Technologies SA (DBVT:NASDAQ) while raising their price target to US$7.00 from US$5.00. The report follows DBV's announcement of regulatory clarity regarding the path forward for its Viaskin Peanut patch.

The analysts highlighted the significance of the FDA agreement, stating, "DBV Technologies has reached an agreement with the FDA regarding the regulatory pathway for the Viaskin Peanut patch in toddlers aged one to three, under the Accelerated Approval pathway."

Regarding the company's development timeline, the analysts noted, "The Biologics License Application (BLA) submission for Viaskin Peanut in this age group is expected to be supported by positive efficacy and safety data from DBV's completed EPITOPE Phase 3 study, as well as additional safety data from the upcoming six-month COMFORT Toddlers supplemental safety study, which is expected to begin in 2Q25."

The report emphasized the strength of DBV's regulatory position, stating, "The FDA has stated that DBV has already satisfied two of the three criteria: the product treats a serious condition, and the product candidate provides a meaningful advantage over available therapies."

The analysts also highlighted progress in Europe, noting, "The EMA confirmed that the successfully completed EPITOPE Phase 3 efficacy and safety trial in the one to three-year-old population, along with positive results from the VITESSE study in the four to seven-year-old population, and a new safety study using the modified circular patch in one to three-year-olds, could support an MAA for the one to seven-year-old indication with the modified patch."

The analysts' valuation methodology for DBV Technologies is based on a composite approach. They explained, "Our US$7 price target is based on an equally weighted composite of: (a) US$5.10/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of US$5.13 discounted back to FY24 at 35%; and (b) an NPV of US$8.52/share with a 13% discount rate and 1% growth rate."

The report included commercial projections, with the analysts stating, "We continue to model initial approval in 2027, with projected initial sales of US$17.5M, growing to US$1,182.8M by 2034."

The analysts also outlined several risk factors, including potential clinical study failures, regulatory approval challenges, and market size uncertainties.

In conclusion, H.C. Wainwright & Co.'s increased price target to US$7 reflects growing confidence in DBV Technologies' regulatory pathway for the Viaskin Peanut patch. The share price at the time of the report of US$0.70 represents a potential return of approximately 900% to the analysts' target price, highlighting the significant upside potential if the company successfully navigates the regulatory process and commercializes its product.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co. DBV Technologies S.A., October 23, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Andrew S. Fein, Matthew Caufield, Andres Y. Maldonado, PhD and Ananda Ghosh, PhD , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of DBV Technologies S.A. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of DBV Technologies S.A.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from DBV Technologies S.A. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from DBV Technologies S.A. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in DBV Technologies S.A. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: DBVT:NASDAQ, )

Communities in the Gulf of Mexico are especially familiar with the whims of nature and power of the sea. This year’s hurricane season has already brought power outages, heavy rain, downed trees, and death and injury. Roy Wright talks about the compounding effects and lasting impacts of disasters on shaping resiliency in the Gulf.

Carol C. Wright is being recognized for inspiring dedication to nursing and to senior advocacy

Brenton Wright is the founder and CEO of Virely LLC, a Software as a Service marketing technology firm

Karlene Wright, DDS channels years of experience into her work with Aesthetic Family Dentistry of Columbia

Geraldine Mulhall-Wright, DC, FICPA, CACCP, recognized for more than 25 years of success as a chiropractor.

Shabazz Arts will launch a Kickstarter campaign for their new graphic novel, Bearcat Wright & The Kayfable Chronicles. The book tells the story of Wright, the first African American pro-wrestling champion.

Mr. Wright is a dedicated educator and coach

Empowering Readers to Overcome Adversity and Embrace Resilience

Former Teacher, Abdul Wright on Technology in the Educational System today

Get ready to groove like never before when the electrifying Disco Divas unite in the First Ladies of Disco Show – it's the Original Ultimate Flashback Experience you've been waiting for!

Mr. David R. Wright is the founder and board chair at Ten 2 Seven, Inc.

Get ready to groove like never before when the electrifying Disco Divas unite in the First Ladies of Disco Show – it's the Original Ultimate Flashback Experience you've been waiting for!

NRCgov posted a photo:

Commissioner Wright and Commissioner Crowell visit Commonwealth Fusion Systems in Massachusetts. CFS is one of several firms seeking to use nuclear fusion (where hydrogen atoms combine to form helium) to generate electricity. The company is currently developing a system using powerful magnetic fields to control the extremely hot plasma that sustains a fusion reaction.

Visit the Nuclear Regulatory Commission's website at www.nrc.gov/.
Photo Usage Guidelines: www.flickr.com/people/nrcgov/
Privacy Policy: www.nrc.gov/site-help/privacy.html.
For additional information, or to comment on this photo contact us via e-mail at: OPA.Resource@nrc.gov.

Scroll down for how to subscribe, transcript, and more My guest for Episode #518 of the Lean Blog Interviews Podcast is Jerry Wright, author of the new book The Insanity Trap: What Your MRP Consultant Won't Tell You. Jerry M. Wright, PE, MBA, is an accomplished operations executive and teaching professional with over 39 years of experience in the manufacturing and service sectors.  His extensive career spans various industries, including aerospace, consumer goods, healthcare, medical […]

The post Breaking the MRP Insanity Trap: Jerry Wright on Lean Systems and Supply Chain Transformation by Mark Graban appeared first at Lean Blog.

Hyrum Wright, Senior Staff Engineer at Google, discusses the book he co-edited, “Software Engineering at Google,” with host Gregory M. Kapfhammer. Wright describes the professional and technical best practices adopted by the software engineers at Google. The wide-ranging conversation investigates an array of topics, including measuring engineering productivity and writing effective test cases. This episode is sponsored by the Algorand Foundation.

The musician behind 2007's 'Rufus Does Judy at Carnegie Hall' will stream his digital performance from Capitol Studios in Los Angeles where he is joined by Kristin Chenoweth and Renee Zellweger.

Rick Wright’s Greenville Triumph have advanced to the United Soccer League [USL] League One play-off semi-finals after beating One Knoxville 2-1 at home yesterday [November 2]. Goals from Evan Lee and a Lyam MacKinnon penalty handed Greenville victory. Greenville will travel to Union Omaha or host Richmond next weekend depending on the outcome of the […]

Rick Wright’s Greenville Triumph lost 2-1 away to Union Omaha in the USL League One play-off semi-finals yesterday [November 9], and one one of the goals scored by Union Omaha was actually scored by Bermudian Zeiko Lewis. A former Saltus Grammar School student, Wright made appearances for the Bermuda and United States national teams. He was appointed […]

Chipotle’s new chief executive is Scott Boatwright, a familiar face and name, given that he’s served as the interim CEO since August following former CEO Brian Niccol’s surprise decision to lead a turnaround at Starbucks. And while Boatwright, 52, will get a significant pay boost in his new…

Bryce Cartwright admits he has something of a split personality in his first NSW State of Origin camp.

Time-hopping film Here used AI trained on every Tom Hanks movie to make him appear young again.

The leading global hospitality and travel technology company, HotelRunner, is excited to announce its attendance at The Phocuswright Conference, running from November 19 to 21, 2024, in Phoenix, Arizona. As a proud sponsor, HotelRunner will join the top industry thought leaders at the JW Marriott Desert Ridge Resort & Spa this year.

Oxford : Archaeopress Publishing Ltd, [2015]

Signing Blondie to our label made us tens of millions

1. NRL 2020: Erin Molan condemns ‘incredibly dangerous’ Holocaust Instagram post, Bryce Cartwright wife  NEWS.com.au
2. Gold Coast Titans anti-vaccination: Doctor’s warning over flu jab after NRL players stood down  Gold Coast Bulletin
3. NRL 2020, news: Bryce Cartwright’s wife hits out in flu shot storm, Instagram post, anti-vaccination players react  NEWS.com.au
4. NRL: Anti-vaxxers stood down as vaccination debate rages on  news.com.au
5. 'It's a team sport boys': Cronulla skipper Wade Graham calls out anti-vaxxers  Wide World of Sports
6. View Full coverage on Google News

Tune into our new show Fox League Live on Channel 502 Monday to Friday at 6.30pm and on Saturday at 3pm and Sunday at 5pm.

Bryce Cartwright’s wife has hit out again after the NRL star was stood down for refusing to accept a flu shot ahead of the season restart on May 28, while more footy players have gone public with their support for people’s right to choose what goes into their bodies.

He's a two-time Oscar winner taking some downtime to accompany his daughter to the beach for a sunny weekend outing.

Archives, Room Use Only - TK5261.P77 1914

"At the end of the day, you want to pick the best position and hopefully it's a good sign that people are starting to value the linebacker position."

In the first volume of the Secret Smithsonian Adventures graphic-novel series from Smithsonian Books, The Wrong Wrights, four middle-school kids visit the Smithsonian’s National Air […]

The post ‘The Wrong Wrights’: A Graphic Novel from Smithsonian Books appeared first on Smithsonian Insider.

Click photo to take a tour of the 1903 Wright Flyer with Smithsonian X 3D Explorer. The Smithsonian X 3D Collection features objects from the […]

The post Take a 3D tour of the 1903 Wright Flyer! appeared first on Smithsonian Insider.

The flower flower motif-stamped Los Angeles masterpiece is set to reopen as a museum following renovations.

The R.W. Lindholm Residence is the newest, but certainly not the first, Wright-designed structure to be relocated in its entirety.

Blue Homes' view-ready Balance prefab finds a most appropriate home on the ancestral stomping grounds of Frank Lloyd Wright in Wisconsin.

In the bucolic exburbs of New York City, a mass-produced home designed by the legendary architect hits the market.

Named to the Top 10 and Best in Atlanta for Plastic Surgery, Dr. Jones specializes in breast, body and facial surgeries